Methods of anti-A/B antibodies elimination in preparation for ABО incompatible kidney transplantation

Main Article Content

R.O. Zograbian
V.P. Zakordonetz
A.I. Malyk
N.M. Polonchuk


Kidney transplantation is considered the gold standard in the treatment of end-stage renal disease and can be performed if cadaveric or living related donor organ is available. AB0 incompatible kidney transplantation can lead to antibody-mediated rejection. There are a number of methods in the world for the elimination of anti-A/B antibodies to prepare for AB0 incompa­tible kidney transplantation, each of which has its advantages and disadvantages. Therefore, further researches are needed in this direction to determine the optimal method in each case. Particular attention is paid to modern methods of anti-A/B antibodies elimination, protocols for managing such patients, and their comparison. The possibilities of using these methods in Ukraine are analyzed.

Article Details

How to Cite
Zograbian, R., V. Zakordonetz, A. Malyk, and N. Polonchuk. “Methods of Anti-A/B Antibodies Elimination in Preparation for ABО Incompatible Kidney Transplantation”. KIDNEYS, vol. 10, no. 2, July 2021, pp. 124-8, doi:10.22141/2307-1257.10.2.2021.234333.


Ministry of Health of Ukraine; Institute of Hematology and Transfusiology of the National Academy of Medical Sciences; Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine. Vyznachennja grup krovi za systemoju AV0, rezus ta imunyh antytil: instrukcija [Determination of blood groups by system AB0, rhesus and immune antibodies: a guideline]. Kyiv; 1999. 1-47 pp. (in Ukrainian).

Lapovets LJe, Lucyk BD. Laboratorna imunologija [Laboratory immunology]. Kyiv; 2004. 64-66 pp. (in Ukrainian).

Gautier SV, Porunova AK, Morozova VV, Tsirulnikova IE, Tsirulnikova OM. Sposob titrovaniia gruppovykh antitel sistemy AV0 [Method for titration of group antibodies of the AB0 system]. Patent RU2526820C1, 2013. (in Russian).

Pierson RN 3rd, Loyd JE, Goodwin A, et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation. 2002 Jul 15;74(1):79-84. doi:10.1097/00007890-200207150-00014.

Chirnside A, Urbaniak SJ, Prowse CV, Keller AJ. Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol. 1981 Aug;48(4):627-634. doi:10.1111/j.1365-2141.1981.00627.x.

Domen RE, Kennedy MS, Jones LL, Senhauser DA. Hemostatic imbalances produced by plasma exchange. Transfusion. 1984 Jul-Aug;24(4):336-339. doi:10.1046/j.1537-2995.1984.24484275577.x.

Huestis DW. Risks and safety practices in hemapheresis procedures. Arch Pathol Lab Med. 1989 Mar;113(3):273-278.

Agishi T, Kaneko I, Hasuo Y, et al. Double filtration plasmapheresis. 1980. Ther Apher. 2000 Feb;4(1):29-33.

Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-32. doi:10.1097/

Higgins R, Lowe D, Hathaway M, et al. Double filtration plasmapheresis in antibody-incompatible kidney transplantation. Ther Apher Dial. 2010 Aug 1;14(4):392-399. doi:10.1111/j.1744-9987.2010.00821.x.

Hanafusa N, Kondo Y, Suzuki M, Nakao A, Noiri E, Fujita T. Double filtration plasmapheresis can decrease factor XIII Activity. Ther Apher Dial. 2007 Jun;11(3):165-170. doi:10.1111/j.1744-9987.2007.00433.x.

Lin SM, Yeh JH, Lee CC, Chiu HC. Clearance of fibrinogen and von Willebrand factor in serial double-filtration plasmapheresis. J Clin Apher. 2003;18(2):67-70. doi:10.1002/jca.10052.

Yeh JH, Chen WH, Chiu HC. Hemodynamic study of serial double-filtration plasmapheresis. J Clin Apher. 2002;17(1):33-37. doi:10.1002/jca.10002.

Belàk M, Borberg H, Jimenez C, Oette K. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci. 1994 Dec;15(4):419-422. doi:10.1016/0955-3886(94)90174-0.

Belák M, Widder RA, Brunner R, Borberg H, Haupt WF. Immunoadsorption with protein A sepharose or silica. Lancet. 1994 Mar 26;343(8900):792-793. doi:10.1016/s0140-6736(94)91868-6.

Rabitsch W, Knöbl P, Greinix H, et al. Removal of persisting isohaemagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2003 Nov;18(11):2405-2408. doi:10.1093/ndt/gfg364.

Wahrmann M, Schiemann M, Marinova L, et al. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. Nephrol Dial Transplant. 2012 May;27(5):2122-2129. doi:10.1093/ndt/gfr610.

Tydén G, Kumlien G, Efvergren M. Present techniques for antibody removal. Transplantation. 2007 Dec 27;84(12 Suppl):S27-9. doi:10.1097/

Schwenger V, Morath C. Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant. 2010 Aug;25(8):2407-2413. doi:10.1093/ndt/gfq264.

Terman DS, Petty D, Harbeck R, Carr RI, Buffaloe G. Specific removal of DNA antibodies in vivo by extracorporeal circulation over DNA immunobilized in collodion charcoal. Clin Immunol Immunopathol. 1977 Jul;8(1):90-96. doi:10.1016/0090-1229(77)90095-2.

Terman DS, Tavel T, Petty D, Racic MR, Buffaloe G. Specific removal of antibody by extracorporeal circulation over antigen immobilized in collodion-charcoal. Clin Exp Immunol. 1977 Apr;28(1):180-188.

Terman DS, Buffaloe G, Mattioli C, et al. Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet. 1979 Oct 20;2(8147):824-827. doi:10.1016/s0140-6736(79)92177-9.

Bensinger WI, Baker DA, Buckner CD, Clift RA, Thomas ED. Immunoadsorption for removal of A and B blood-group antibodies. N Engl J Med. 1981 Jan 15;304(3):160-162. doi:10.1056/NEJM198101153040308.

Alexandre GP, Squifflet JP, De Bruyère M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987 Dec;19(6):4538-4542.

Bannett AD, McAlack RF, Raja R, Baquero A, Morris M. Experiences with known ABO-mismatched renal transplants. Transplant Proc. 1987 Dec;19(6):4543-4546.

Rydberg L, Nyberg G, Attman PO, Mjörnstedt L, Tufveson G, Blohme I. Characterization of the anti-A antibody binding in an ABO-incompatible living donor renal transplantation. Nephrol Dial Transplant. 1994;9(8):1162-1165. doi:10.1093/ndt/9.8.1162.

Takahashi K. Accommodation in ABO-incompatible kidney transplantation: why do kidney grafts survive? Transplant Proc. 2004 Mar;36(2 Suppl):193S-196S. doi:10.1016/j.transproceed.2004.01.070.

Tanabe K, Tokumoto T, Ishida H, et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. Transplant Proc. 2004 Sep;36(7):2175-2177. doi:10.1016/j.transproceed.2004.08.142.

Kumlien G, Ullström L, Losvall A, Persson LG, Tydén G. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion. 2006 Sep;46(9):1568-1575. doi:10.1111/j.1537-2995.2006.00927.x.

Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation. 2003 Aug 27;76(4):730-731. doi:10.1097/01.TP.0000078622.43689.D4.

Most read articles by the same author(s)